GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK said: “This collaboration builds on GSK’s targeted investment in next-generation technologies to advance cancer medicines with transformative potential. By combining our scientific expertise with LTZ’s innovative immune-engager platform, we aim to accelerate first-in-class myeloid cell engager therapies in haematologic cancers and solid tumours to transform outcomes with a safety profile to enable broad community access for people living with cancer.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.